Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Flexibility in surface-exposed loops in a virus capsid mediates escape from antibody neutralization.

Kolawole AO, Li M, Xia C, Fischer AE, Giacobbi NS, Rippinger CM, Proescher JB, Wu SK, Bessling SL, Gamez M, Yu C, Zhang R, Mehoke TS, Pipas JM, Wolfe JT, Lin JS, Feldman AB, Smith TJ, Wobus CE.

J Virol. 2014 Apr;88(8):4543-57. doi: 10.1128/JVI.03685-13. Epub 2014 Feb 5.

2.

Newly isolated mAbs broaden the neutralizing epitope in murine norovirus.

Kolawole AO, Xia C, Li M, Gamez M, Yu C, Rippinger CM, Yucha RE, Smith TJ, Wobus CE.

J Gen Virol. 2014 Sep;95(Pt 9):1958-68. doi: 10.1099/vir.0.066753-0. Epub 2014 Jun 4.

3.
4.

High-resolution x-ray structure and functional analysis of the murine norovirus 1 capsid protein protruding domain.

Taube S, Rubin JR, Katpally U, Smith TJ, Kendall A, Stuckey JA, Wobus CE.

J Virol. 2010 Jun;84(11):5695-705. doi: 10.1128/JVI.00316-10. Epub 2010 Mar 24.

5.

Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002.

Lindesmith LC, Debbink K, Swanstrom J, Vinjé J, Costantini V, Baric RS, Donaldson EF.

J Virol. 2012 Jan;86(2):873-83. doi: 10.1128/JVI.06200-11. Epub 2011 Nov 16.

6.

Structure of antibody-neutralized murine norovirus and unexpected differences from viruslike particles.

Katpally U, Wobus CE, Dryden K, Virgin HW 4th, Smith TJ.

J Virol. 2008 Mar;82(5):2079-88. Epub 2007 Dec 19.

7.

Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope.

Lindesmith LC, Donaldson EF, Beltramello M, Pintus S, Corti D, Swanstrom J, Debbink K, Jones TA, Lanzavecchia A, Baric RS.

J Virol. 2014 Aug;88(16):8826-42. doi: 10.1128/JVI.01192-14. Epub 2014 May 28.

8.

Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity.

Debbink K, Lindesmith LC, Donaldson EF, Costantini V, Beltramello M, Corti D, Swanstrom J, Lanzavecchia A, Vinjé J, Baric RS.

J Infect Dis. 2013 Dec 1;208(11):1877-87. doi: 10.1093/infdis/jit370. Epub 2013 Aug 1.

9.

Immunogenetic mechanisms driving norovirus GII.4 antigenic variation.

Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS.

PLoS Pathog. 2012;8(5):e1002705. doi: 10.1371/journal.ppat.1002705. Epub 2012 May 17.

10.

Norovirus GII.4 strain antigenic variation.

Lindesmith LC, Donaldson EF, Baric RS.

J Virol. 2011 Jan;85(1):231-42. doi: 10.1128/JVI.01364-10. Epub 2010 Oct 27.

11.

Protruding domain of capsid protein is necessary and sufficient to determine murine norovirus replication and pathogenesis in vivo.

Strong DW, Thackray LB, Smith TJ, Virgin HW.

J Virol. 2012 Mar;86(6):2950-8. doi: 10.1128/JVI.07038-11. Epub 2012 Jan 18.

12.

Structure of a Human Astrovirus Capsid-Antibody Complex and Mechanistic Insights into Virus Neutralization.

Bogdanoff WA, Campos J, Perez EI, Yin L, Alexander DL, DuBois RM.

J Virol. 2017 Jan 3;91(2). pii: e01859-16. doi: 10.1128/JVI.01859-16. Print 2017 Jan 15.

13.

Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity.

Debbink K, Donaldson EF, Lindesmith LC, Baric RS.

J Virol. 2012 Jan;86(2):1214-26. doi: 10.1128/JVI.06189-11. Epub 2011 Nov 16.

14.

Structural Basis of Human Parechovirus Neutralization by Human Monoclonal Antibodies.

Shakeel S, Westerhuis BM, Ora A, Koen G, Bakker AQ, Claassen Y, Wagner K, Beaumont T, Wolthers KC, Butcher SJ.

J Virol. 2015 Sep;89(18):9571-80. doi: 10.1128/JVI.01429-15. Epub 2015 Jul 8.

15.

Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies.

Dietrich MH, Ogden KM, Katen SP, Reiss K, Sutherland DM, Carnahan RH, Goff M, Cooper T, Dermody TS, Stehle T.

J Virol. 2017 Jan 31;91(4). pii: e01621-16. doi: 10.1128/JVI.01621-16. Print 2017 Feb 15.

PMID:
27928010
16.

Antibody is critical for the clearance of murine norovirus infection.

Chachu KA, Strong DW, LoBue AD, Wobus CE, Baric RS, Virgin HW 4th.

J Virol. 2008 Jul;82(13):6610-7. doi: 10.1128/JVI.00141-08. Epub 2008 Apr 16.

17.

Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains.

Zhu S, Regev D, Watanabe M, Hickman D, Moussatche N, Jesus DM, Kahan SM, Napthine S, Brierley I, Hunter RN 3rd, Devabhaktuni D, Jones MK, Karst SM.

PLoS Pathog. 2013;9(9):e1003592. doi: 10.1371/journal.ppat.1003592. Epub 2013 Sep 5.

18.

Within-host evolution results in antigenically distinct GII.4 noroviruses.

Debbink K, Lindesmith LC, Ferris MT, Swanstrom J, Beltramello M, Corti D, Lanzavecchia A, Baric RS.

J Virol. 2014 Jul;88(13):7244-55. doi: 10.1128/JVI.00203-14. Epub 2014 Mar 19.

19.

Production, characterization and immunogenicity of P particles derived from norovirus GII.4 genotype 2004 variant.

Su W, Gao J, Zang Y, Wu H, Wang L, Hu H, Yu X, Kong W, Jiang C.

Acta Virol. 2015 Mar;59(1):33-9.

PMID:
25790049
20.

Chimeric GII.4 norovirus virus-like-particle-based vaccines induce broadly blocking immune responses.

Debbink K, Lindesmith LC, Donaldson EF, Swanstrom J, Baric RS.

J Virol. 2014 Jul;88(13):7256-66. doi: 10.1128/JVI.00785-14. Epub 2014 Apr 16.

Supplemental Content

Support Center